386768-80-5

Upstream product

• 870-46-2 t-butoxycarbonylhydrazine 
• 24964-64-5 3-Cyanobenzaldehyde 

Downstream Products

• 1221501-75-2 3-{[5-(4-Fluorophenyl)-3-methyl-4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1H-pyrazol-1-yl]methyl}benzonitrile 
• 1221504-20-6 3-{[4-bromo-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-1-yl]methyl}benzonitrile 
• 1221504-19-3 3-{[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-1-yl]methyl}benzonitrile 
• 439926-95-1 N'-(1-Azepanylcarbonyl)-N'-(3-cyanobenzyl)-6-methoxy-2-naphthalenesulfonohydrazide 
• 439926-88-2 N'-(3-Cyanobenzyl)-6-methoxy-N'-[(2-methyl-1-piperidinyl)carbonyl]-2-naphthalenesulfonohydrazide 
• 439926-92-8 C₂₅H₂₆N₄O₃S 
• 439926-79-1 N'-(3-Cyanobenzyl)-N'-[(4-methyl-1-piperidinyl)carbonyl]-2-naphthalenesulfonohydrazide 
• 439926-86-0 N'-(3-cyanobenzyl)-N'-[(2-methyl-1-piperidinyl)carbonyl]-2-naphthalenesulfonohydrazide 
• 439926-84-8 tert-Butyl 2-(1-azepanylcarbonyl)-2-(3-cyanobenzyl)-1-hydrazinecarboxylate 
• 439926-82-6 tert-Butyl 2-(3-cyanobenzyl)-2-[(2-methyl-1-piperidinyl)carbonyl]-1-hydrazinecarboxylate 
• 772332-80-6 azepane-1-carboxylic acid N-(3-cyano-benzyl)-hydrazide 
• 769113-21-5 2-methyl-piperidine-1-carboxylic acid N-(3-cyano-benzyl)-hydrazide 
• 386768-88-3 N'-(3-cyanobenzyl)-6-methoxy-N-[(4-methyl-1-piperidinyl)carbonyl]-2-naphthalenesulfonohydrazide 
• 386768-84-9 tert-butyl 2-(3-cyanobenzyl)-2-[(4-methyl-1-piperidinyl)carbonyl]hydrazinecarboxylate 

Relevant academic research and scientific papers

Thrombin inhibitors built on an azaphenylalanine scaffold

A series of azaphenylalanine derivatives were investigated as novel thrombin inhibitors based on the prodrug principle. By systematic structural modifications we have identified optimal groups for this series that led us to potent inhibitors of thrombin i

PYRAZOLE COMPOUNDS

The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineralocorticoid receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of a disease or condition mediated by the mineralocorticoid receptor activation.

Synthesis and biological activities of topoisomerase I inhibitors, 6-arylmethylamino analogues of edotecarin

The replacement of 1,3-dihydroxy-2-propylamino moiety at the N6-position of edotecarin (1) by arylmethylamino groups yielded a number of more potent topoisomerase I inhibitors with better cytotoxic (CTX) activities in vitro than edotecarin. Among them, th